FTC Requires Divestitures In Barr, Pliva Merger

Law360, New York (October 20, 2006, 12:00 AM EDT) -- Concerned over the anti-competitive effects of Barr Pharmaceutical Inc.’s $2.5 billion acquisition of European generic drug giant Pliva, the U.S. Federal Trade Commission has forced Barr to sell the rights to four of its drug products.

Not forcing the divestitures, the FTC said, would mean that the four related product markets would likely experience a reduction in competition, and consumers would pay more for their drugs.

“Preserving competition in the markets for pharmaceuticals and other health care products to the benefit of U.S. consumers is core...
To view the full article, register now.